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The	major	hormone	involved	with	parturition	 to	stimulate	 uterine	 contractions	 is	 oxytocin.	
Russell	et	al1	have	reviewed	the	extensive	literature	
on	 the	 complexity	 of	 the	 magnocellular	 oxytocin	
system.	 Endogenous	 opioids	 mechanisms	 inhibit	




released	 into	 systemic	circulation	via	 the	posterior	
lobe	of	the	pituitary	gland.	Specifically,	oxytocin	is	
made	 in	 magnocellular	 neurosecretory	 cells	 of	 the	
supraoptic	 nucleus	 and	 paraventricular	 nucleus	 of	
the	 hypothalamus.	 It	 is	 well	 established	 that	 oxy-
tocin	is	involved	in	a	positive	feedback	loop	during	
parturition,	 in	 which	 oxytocin	 causes	 uterine	 con-
tractions,	 which	 in	 turn	 lead	 to	 more	 oxytocin	
release.	This	feed-forward	loop	continues	until	par-
turition.	 Oxytocin	 is	 also	 released	 when	 an	 infant	
suckles	at	the	nipple	of	a	lactating	mother	and	acts	
at	 the	 mammary	 glands,	 causing	 milk	 letdown.	 In	










nal	 pain	 relief	 in	 labor	 is	 especially	 useful.3	 The	
availability	of	a	wide	range	of	analgesics	with	vastly	
different	 pharmacology,	 pharmacokinetics,	 milli-
gram	 potencies,	 routes	 of	 administration,	 and	 side	
effects	 is	 impressive.	 Nevertheless,	 morphine	 use	
during	 labor	has	had	a	checkered	pro	and	con	his-
tory	over	 the	years.	During	 its	use	 to	produce	 twi-
light	 sleep,	 it	became	clear	 that	 although	analgesia	
and	 amnesia	 for	 the	 mother	 was	 desirable,	 some	
women	 became	 excited	 and	 delirious.	 In	 addition,	
newborns	 frequently	 showed	apnea.	Thus,	 twilight	
sleep	 was	 abandoned	 years	 ago.	 Its	 replacement	
with	meperidine	alone	or	in	combination	with	pro-
methazine	also	had	a	pro	and	con	history	of	increased	
use	 to	 abandonment.	 Meperidine	 has	 a	 complex	
pharmacology	in	addition	to	having	mu	opioid	anal-
gesic	properties.	DeVoe	et	al4	reported	that	meperid-
ine	 alone	 or	 in	 combination	 with	 promethazine,	
although	 analgesic,	 did	 not	 decrease	 but	 actually	
increased	uterine	activity	over	control	from	about	7	
to	20-30	Torr/min	units	of	uterine	activity	over	10	to	
30	 minutes.	 Many	 other	 opioids	 have	 been	 used	
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since,	again	with	mixed	results.	Today,	morphine	is	
used	 in	 a	 subset	 of	 obstetrical	 patients	 to	 provide	
rest	and	sedation	as	appropriate	for	the	stressed	pro-
dromal	stages	of	a	 labor	without	sufficient	cervical	
dilation	with	a	 fetus	 in	no	stress.	This	 review	pro-
vides	a	rational	scientific	basis	to	its	current	use	and	
shows	why	 it	 is	useful	 for	more	 than	 just	 rest	 and	
sedation	for	patients.
OPiOid ReCePTORs in The PiTuiTaRy
Controversy	exists	over	the	nature	of	opiate	binding	in	
the	posterior	pituitary.11	C-carfentanil	(a	selective	mu	
opioid	 receptor	 agonist)	 is	 known	 to	 have	 relatively	
high	binding	potential	in	the	human	pituitary	similar	
to	classical	opiate	binding	areas	 in	 the	brain,	but	 its	
clinical	 significance	 remains	 unknown.5,6	 However,	
positron	emission	tomography	(PET)	imaging	does	not	




ing	 the	 presence	 of	 a	 nonopioid	 binding	 site.5,6	 One	
possibility	is	that	a	metabolite	of	11C-carfentanil	such	
as	11C-methanol	may	be	involved.
Simantov	 and	 Snyder7	 reported	 the	 presence	
of	 mu	 opiate	 binding	 in	 bovine	 intermediate	 and	
posterior	 but	 very	 little	 in	 the	 anterior	 pituitary,	
where	 beta-endorphin	 is	 released.8	 Jordan	 et	 al9	
studied	 postmortem	 pituitaries	 from	 5	 human	 par-
ticipants	 without	 neuroendocrine	 or	 neuronal	 dis-
ease.	They	used	(125I)-FK-33-824	for	mu,	(125I)[D.Ala2]
Deltorphin-I	 for	 delta,	 and	 3H-U69,593	 for	 kappa	
opioid	 sites.	 Quantitative	 in	 vitro	 autoradiography	
of	 pituitary	 sections	 with	 each	 radioactive	 ligand	




completely	 but	 had	 no	 significant	 delta	 binding	
sites.	 These	 investigators	 further	 showed	 that	 both	
the	mu	and	kappa	opioid	binding	was	competitively	
antagonized	 by	 other	 selective	 opioid	 ligands.	 The	
more	recent	PET	study	by	Weerts	et	al10	also	demon-
strated	 a	 specific	 mu	 opioid	 binding	 site	 in	 the	
human	pituitary.	These	investigators	studied	mu	as	
well	as	delta	opioid	brain	and	pituitary	binding	 in	
recently	 abstinent	 alcohol-dependent	 participants	
treated	with	naltrexone.	The	naltrexone-treated	subjects	




other	 published	 animal	 and	 human	 pituitary	 data	




Mu OPiOid MOdulaTiOn Of POsTeRiOR 
PiTuiTaRy hORMOne Release
Opioid	binding	 in	 the	posterior	pituitary	 is	 impor-
tant	 because	 of	 the	 effect	 on	 oxytocin	 and	 vaso-
pressin	release.	Both	mu	and	kappa	opioid	receptor	
agonists	have	been	shown	 to	affect	posterior	pitui-
tary	 hormone	 release.	 Oxytocin	 secretion	 is	 inhib-
ited	 centrally	 by	 both	 mu	 and	 kappa	 agonists	 or	
directly	 at	 the	 posterior	 pituitary	 via	 kappa	 recep-
tors.	 Lutz-Bucher	 and	 Koch12	 isolated	 the	 rat	 neu-
rointermediate	as	well	as	the	neural	lobe	(posterior	
pituitary).	 Removal	 of	 the	 endogenous	 opiate-rich	
pars	intermedia	cells	from	the	pars	nervosa	enhanced	
both	 oxytocin	 and	 vasopressin	 release.	 Morphine	
inhibited	their	release	from	both	lobes,	but	the	neu-




vosa	 with	 attached	 pars	 intermedia.	 They	 electri-
cally	 stimulated	 the	 pituitary	 stalk	 to	 measure	
oxytocin	 and	 vasopressin	 release.	 Morphine	 inhib-
ited	both	oxytocin	and	vasopressin	release.	Naloxone	
reversed	 morphine	 inhibition	 of	 oxytocin	 but	 not	
vasopressin	release.	Bicknell	et	al14	found	that	oxy-
tocin	 cells	 develop	 dependence	 with	 added	 mor-
phine	and	eventually	require	morphine	to	function	
normally.	When	naloxone	was	given,	the	firing	rate	
of	 oxytocin-secreting	 cells	 increased	 360%	 and	
plasma	oxytocin	 levels	 increased	100	 times	greater	
than	 in	 controls.	 No	 significant	 difference	 was	
observed	 in	 vasopressin	 levels.	 Zhao	 et	 al15	 also	





given	 intracerebroventricularly	 (ICV)	 and	 intrave-




opioids	 is	 important	 for	 oxytocin	 neurons	 during	
pregnancy,	in	preparation	for	parturition.
Ortiz-Miranda	 et	 al17,18	 reported	 that	 mu	 opioid	
receptors	modulate	rat	neurohypophyseal	terminals	
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by	inhibiting	R-type	Ca2+	channels.	The	mu	receptor	
agonist,	 [D-Ala2,	 N-Me-Phe4,	 Gly5-ol]-enkephalin	
(DAMGO),	inhibited	oxytocin	more	than	vasopressin	
release.	 The	 inhibitory	 actions	 of	 DAMGO	 were	
antagonized	 by	 the	 mu	 antagonist	 CTOP	 (D-Phe-	
Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr	amide).
KaPPa OPiOid MOdulaTiOn Of POsTeRiOR 
PiTuiTaRy hORMOne Release
Zhao	 et	 al,15,19	 Bicknell	 et	 al,20	 Kato	 et	 al,21	 and	
Russell	 et	 al22	 emphasized	 the	 importance	of	 func-
tional	kappa	receptors	on	oxytocin	and	vasopressin	
rat	posterior	pituitary	terminals,	with	a	greater	inhi-
bition	 on	 oxytocin	 than	 vasopressin	 release.	 Mu	
agonists	do	not	have	as	great	of	 an	effect	 as	kappa	
agonists	 at	 oxytocin	 and	 vasopressin	 nerve	 termi-
nals.22,23	Russell	et	al22	found	that	the	kappa	agonist	
U50,488	 inhibited	 electrically	 stimulated	 oxytocin	
release	in	rats,	but	morphine	had	no	effect.	U50,488	
had	no	effect	on	mammary	gland	sensitivity	to	oxy-
tocin,	 whereas	 morphine	 decreased	 sensitivity.	
These	 results	 suggest	 that	mu	 receptors	 located	on	
the	 posterior	 pituitary	 are	 not	 coupled	 to	 mecha-
nisms	 regulating	 release	 of	 oxytocin	 but	 are	 rather	





ously	 (SC)	 or	 ICV	 to	 water-deprived	 rats	 to	 alter	
plasma	oxytocin	and	vasopressin	levels.	Both	opioid	
antagonists	 given	 SC	 increased	 plasma	 oxytocin.	
Given	ICV,	both	equally	antagonized	coadministered	
dynorphin	 A	 (an	 endogenous	 predominant	 kappa	
receptor	 agonist).	 When	 either	 beta-endorphin	 or	
dynorphin	A	were	given	ICV,	the	quaternary	antago-




tion	 of	 oxytocin	 release	 was	 equally	 antagonized	
by	both	opioid	antagonists,	suggesting	an	action	out-
side	 of	 the	 blood-brain	 barrier	 (ie,	 in	 the	 posterior	
pituitary).	In	a	different	experiment,	Van	de	Heijning	
et	 al25	 again	 found	 that	 mu	 and	 kappa	 but	 not	
delta	opioid	 receptors	are	 involved	 in	 the	modula-
tion	 of	 vasopressin	 and	 oxytocin	 release	 in	 rats.	
The	 mu	 opioid	 receptor	 agonist	 DALDA	 (H-Tyr-D-
Arg-Phe-Lys-NH2)	given	SC	and	 ICV	inhibited	both	
vasopressin	and	oxytocin	release.	The	kappa	opioid	
receptor	 agonist	 U-69,593	 inhibited	 the	 release	 of	
vasopressin	 and	 oxytocin	 when	 given	 SC	 but	 not	
when	given	ICV,	again	indicating	action	at	the	poste-
rior	pituitary	 for	a	kappa	agonist.	Both	kappa	(nor-
binaltorphimine)	 and	 mu	 (naloxone)	 but	 not	 delta	
(naltrindole)	 antagonists	 increased	 oxytocin	 levels,	
but	 when	 given	 ICV,	 only	 the	 kappa	 antagonist	
enhanced	both	oxytocin	and	vasopressin	release.
Dayanithi	et	al26	used	rat	neural	lobes	and	isolated	
nerve	 terminals	 to	 show	kappa	agonist	 inhibition	of	
oxytocin	 more	 than	 vasopressin	 release	 as	 well	 as	
antagonism	 by	 naloxone.	 There	 were	 a	 number	 of	
















oid	 peptides	 inhibit	 their	 release	 both	 within	 the	
hypothalamus	and	at	their	terminals	in	the	pituitary	
itself.	 Furthermore,	 the	 co-localization	 in	 neurose-
cretory	 granules	 and	 subsequent	 co-release	 of	 the	
kappa	agonist,	dynorphin,	with	vasopressin	appears	
to	reduce	oxytocin	release	from	the	latter’s	axon	ter-
minals.	 Oxytocin	 cells	 also	 synthesize	 dynorphin	
and	enkephalins.	The	co-release	of	endogenous	opi-
oids	 appears	 to	 reduce	 oxytocin	 release	 more	 than	
vasopressin.	 Bicknell	 and	 Leng28	 concluded	 that	
endogenous	 opioid	 receptor	 agonists	 only	 act	 to	
inhibit	 oxytocin	 release,	 with	 no	 effect	 on	 vaso-
pressin	release	in	rat	posterior	pituitary.	Also	in	rats,	
Bondy	 et	 al29	 found	 that	 dynorphin	 A	 (an	 endog-
enous	predominant	kappa	receptor	agonist)	inhibits	
the	 electrically	 stimulated	 release	 of	 oxytocin	 but	
not	vasopressin	 from	the	 terminals	of	 the	posterior	
pituitary.	 However,	 Shuster	 et	 al30	 conclude	 from	
their	 studies	 in	 guinea	 pigs	 that	 dynorphin-	






plasma	 oxytocin	 levels.	 The	 researchers	 found	 a	
decrease	 in	 oxytocin	 30	 minutes	 after	 injection,	
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much	like	in	other	studies.	However,	after	4	hours,	
oxytocin	 levels	 increased	 20-fold.	 Two	 possible	
explanations	 for	 this	 phenomenon	 were	 given:	 (1)	





oxytocin	 release	 could	 have	 important	 clinical	
implications	 related	 to	 pregnancy	 and	 parturition.	




period	 of	 rest.	 When	 the	 effects	 of	 the	 drug	 wear	
off,	 normal	 uterine	 contractions	 often	 follow	 per-
haps	due	to	increased	endogenous	oxytocin	release.	
Theoretically,	a	mu	agonist	such	as	morphine	would	
be	 preferred	 because	 of	 the	 dysphoric	 and	 psy-
chotomimetic	 properties	 of	 kappa	 opioid	 receptor	
agonists.32
CliniCal use Of OPiOids in ObsTeTRiCs
A	wide	range	of	opioid	analgesics	can	be	considered	
by	 physicians	 and	 midwives	 for	 laboring	 patients	
requesting	 pain	 relief	 outside	of	 when	a	 labor	 epi-
dural	is	available.	The	opioid	analgesic	meperidine	
was	 previously	 a	 popular	 narcotic	 in	 this	 field.	
However,	 it	 has	 been	 restricted	 in	 many	 hospitals	
due	to	a	variety	of	dangerous	side	effects	(confusion,	
anxiety,	 hallucinations,	 tremors,	 and	 seizures),	 a	
shorter	analgesic	period	than	morphine,	and	poten-
tially	 fatal	 interactions	 with	 monoamine	 oxidase	
inhibitors.33-35
Intrathecal	and	epidural	administration	of	opioids	
by	 anesthesiologists	 is	 a	 common	 analgesic	 method	








in	 latent	 labor	 with	 analgesia	 and	 rest,	 and	 contrac-
tions	may	ease	soon	after	injection.	In	1955,	Friedman38	
noted	 from	 observations	 of	 46	 patients	 with	 uterine	
inertia	that	almost	half	were	due	to	excessive	medica-
tion.	 Unfortunately,	 his	 article	 did	 not	 specify	 the	
medication(s)	given.	Most	women	awaken	from	“ther-
apeutic	 rest”	 from	 morphine	 in	 active	 labor.39	 Of	
course,	respiratory	depression	of	the	newborn	can	be	an	
issue	when	large	doses	of	morphine	are	used.






established,	 however,	 it	 was	 not	 affected	 by	 mor-







nancy.41	 The	 specific	 opioid	 system	 responsible	 for	
the	 control	 of	 oxytocin	 secretion	 during	 pregnancy	
until	 parturition	 changes	 with	 time.	 Douglas	 et	 al41	
found	 that	 on	 days	 15,	 18,	 and	 21	 of	 pregnancy	 in	
rats,	naloxone	caused	a	significant	increase	in	plasma	
oxytocin	levels,	suggesting	endogenous	opioid	inhibi-
tion	of	 oxytocin	 release.	Naloxone	 failed	 to	 cause	 a	





nonpregnant	 rats.	 This	 indicates	 desensitization	 of	
oxytocin	nerve	terminals	to	endogenous	kappa	opioid	
suppression	 late	 in	 pregnancy.	 Douglas	 et	 al41	 also	





not	 change	 during	 pregnancy.	 The	 researchers	 con-
cluded	 that	 a	 product	 of	 proenkephalin	 A	 is	 likely	
responsible	 for	 autoinhibition	 of	 oxytocin	 release	
during	pregnancy.







oxytocin	 levels,	 again	 indicating	 that	 endogenous	
kappa	 opioid	 receptors	 are	 downregulated.	 Other	
research	suggests	that	mu	opioid	receptors	mediate	
oxytocin	 release	 at	 the	 time	 of	 parturition.	 Kutlu	
et	al43	studied	oxytocin	levels	in	pregnant	and	partu-
rient	rats	given	ICV	morphine	(mu	agonist),	U50,488H	
(kappa	 agonist),	 clocinnamox	 (mu	 antagonist),	 and	
norBNI	 (kappa	 antagonist).	 Parturient	 rats	 had	
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increased	 levels	 of	 oxytocin	 and	 decreased	 levels	
of	 beta-endorphin	 compared	 to	 20-day	 pregnant	
rats.	 Clocinnamox	 raised	 oxytocin	 levels,	 whereas	
U50,488H	decreased	oxytocin	 levels.	An	important	
finding	 was	 that	 only	 clocinnamox	 elevated	 nor-
epinephrine	 in	 the	 supraoptic	 nucleus	 and	 the	
paraventricular	nucleus.	Norepinephrine	has	a	stim-
ulatory	 effect	 on	 oxytocin	 neurons.44	 Thus,	 Kutlu	
et	 al43	 concluded	 that	 endogenous	 mu	 opioid	 ago-
nists	 cause	 tonic	 inhibition	 of	 oxytocin	 neurons	
at	 presynaptic	 norepinephrine	 terminals	 in	 the	
hypothalamus—tonic	 because	 only	 cloccinnamox	
raised	oxytocin	levels,	and	morphine	had	no	effect.	
The	 decrease	 in	 oxytocin	 levels	 produced	 by	
U50,488H	were	likely	due	to	actions	directly	on	the	
posterior	pituitary.
In	 addition,	 hypothalamic	 mu	 opioid	 receptor	




Hypothalamic	 beta-endorphin	 levels	 followed	 the	
same	 pattern	 in	 this	 study—an	 increase	 up	 to	 the	
point	of	parturition	and	a	subsequent	decrease	back	





receptor	 and	 beta-endorphin	 concentrations	 after	
parturition	 is	 important	 for	 the	 development	 of	
maternal	 behavior	 and	 for	 the	 control	 of	 oxytocin	
release.	Oxytocin	 is	 important	 in	 controlling	 lacta-
tion.	 Thus,	 opioid	 suppression	 of	 oxytocin	 release	
must	 be	 decreased	 for	 lactation	 to	 occur	 properly.	
Boersma	 et	 al46	 and	 Douglas	 and	 Russell47	 have	
emphasized	 neural-glial	 interactions	 in	 the	 release	
of	 oxytocin,	 vasopressin,	 ACTH,	 and	 the	 role	 of	
opioids	and	other	peptides.	In	addition,	endogenous	
opioids	regulate	intracerebral	release	of	oxytocin	in	
a	 region-specific	 manner.48	 In	 addition,	 the	 impor-
tant	role	of	infant-mother	attachment	involves	con-








and	delays	childbirth	 is	 likely	due	 to	 inhibition	of	
oxytocin	release.	As	the	drug	wears	off	or	as	opioid	
receptors	 are	 downregulated,	 oxytocin	 levels	





tered	 if	 needed	 to	 counteract	 newborn	 complica-
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